Distant metastases occur in 50% of cases of HCC. Bones are involved in 11% with the spine as the most important localization. In the reported case a tumorous mass in the liver, suspicious for HCC according to clinical and cytological criteria, was proved to be malignant by the cytologic examination of a metastasis to the sacrum.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Usage of Milan System in Risk Stratification of Submandibular Gland Fine Needle Aspiration Cytology.
Laryngoscope
January 2025
Department of Otorhinolaryngology, Tan Tock Seng Hospital, Singapore, Singapore.
Objectives: The Milan System for Reporting Salivary Gland Cytopathology (MSRSGC) categorizes fine needle aspiration and cytology (FNAC) results into 6 tiers and assigns a risk of malignancy (ROM) to each category. Its utility in submandibular gland lesions remains unclear. Our article aims to study (1) the utility of the MSRSGC in classifying FNAC of submandibular gland masses, (2) describe the demographics and incidence of submandibular gland malignancy in our population, and (3) analyze the accuracy of FNAC in diagnosis of benign and malignant submandibular gland tumors.
View Article and Find Full Text PDFResponse to: Site of puncture in endoscopic ultrasound-guided fine needle biopsy: Does it change diagnostic outcome?
Dig Endosc
January 2025
Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Insights in biomarkers complexity and routine clinical practice for the diagnosis of thyroid nodules and cancer.
PeerJ
January 2025
Instituto de Patologia e Imunologia Molecular da Universidade do Porto (IPATIMUP), i3S-Institute for Research & Innovation in Health, Porto, Portugal.
Background: The differential diagnosis between benign and malignant thyroid nodules continues to be a major challenge in clinical practice. The rising incidence of thyroid neoplasm and the low incidence of aggressive thyroid carcinoma, urges the exploration of strategies to improve the diagnostic accuracy in a pre-surgical phase, particularly for indeterminate nodules, and to prevent unnecessary surgeries. Only in 2022, the 5th WHO Classification of Endocrine and Neuroendocrine Tumors, and in 2023, the 3rd Bethesda System for Reporting Thyroid Cytopathology and the European Thyroid Association included biomarkers in their guidelines.
View Article and Find Full Text PDFClaudin 18.2: An attractive marker in pancreatic ductal adenocarcinoma.
Oncol Lett
March 2025
Department of Pathology, National Institute of Gastroenterology, IRCCS 'S. de Bellis' Research Hospital, Castellana Grotte, I-70013 Bari, Italy.
Pancreatic ductal adenocarcinoma (PDA) is a highly aggressive tumor with limited treatment options. Zolbetuximab, a monoclonal antibody against the tight junction protein Claudin 18.2 has recently been developed.
View Article and Find Full Text PDFThy1c Cytology Is a Reliable Method of Excluding Thyroid Cancer in Dominant Cystic Nodules.
Cytopathology
January 2025
Department of Endocrine Surgery, University Hospital of Wales, Cardiff, UK.
Background: Traditional teaching dictated that patients with recurrent thyroid cysts undergo excision owing to a 12% risk malignancy. Ultrasound evaluation now determines management of these patients augmented by fine needle biopsy. In UK, a non-diagnostic category for thyroid cysts (Thy1c) exists, whereas the Bethesda system combines 'non-diagnostic-cyst fluid only' into Category I along with paucicellular and acellular results.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!